文献速递乳腺癌

三阴性乳腺癌辅助化疗决策影响因素分析

[Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

回顾性分析瑞金医院2013年4月至2015年6月194例接受手术和MDT讨论的浸润性三阴性乳腺癌患者,主诊医师与MDT团队化疗决策改变率为22.7%(39/172),其中94.9%(37/39)为化疗方案不一致;E1199结果公布后推荐EC序贯每周紫杉醇方案增多,化生性癌患者更多推荐含铂方案。

要点

  • 194例≤70岁患者中187例(96.4%)被推荐化疗,主诊医师与MDT化疗决策改变率为22.7%(39/172)。
  • 决策改变中94.9%(37/39)为化疗方案不一致;E1199结果公布后EC-T比例由62.5%(55/88)降至22.6%(7/31),EC-wP由37.5%(33/88)升至77.4%(24/31)(P<0.001)。
  • 20例推荐含铂方案,浸润性导管癌占9.3%(15/162),化生性癌占33.3%(5/15)(P=0.016)。

核心结论

  • MDT模式下三阴性乳腺癌辅助化疗决策改变率为22.7%。
  • SABCS E1199结果公布后,推荐EC序贯每周紫杉醇辅助化疗方案增多。
  • 铂类在三阴性乳腺癌辅助化疗中缺乏详实数据,较多化生性癌患者接受含铂类辅助化疗。

研究设计与样本

  • 回顾性分析2013年4月至2015年6月在上海交通大学医学院附属瑞金医院乳腺疾病诊治中心接受手术和MDT讨论并制订术后辅助治疗方案的浸润性三阴性乳腺癌患者。

主要发现

  • 194例≤70岁患者中187例(96.4%)被推荐化疗。
  • 主诊医师与MDT团队意见不一致导致化疗决策改变率达22.7%(39/172),其中94.9%(37/39)为化疗方案改变。
  • 119例被推荐EC-T或wP方案;E1199结果公布前EC-T占62.5%(55/88)、EC-wP占37.5%(33/88),公布后EC-T降至22.6%(7/31)、EC-wP升至77.4%(24/31)(P<0.001)。
  • 20例被推荐含铂类方案,浸润性导管癌中占9.3%(15/162),化生性癌中占33.3%(5/15)(P=0.016)。

关键数值与推荐

  • 化疗决策改变定义为主诊医师和MDT团队在化疗与否或化疗方案的意见不一致。
  • EC-T方案为表柔比星联合环磷酰胺序贯多西他赛;wP方案为每周紫杉醇。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze adjuvant chemotherapy decisions for triple negative breast cancer (TNBC), and explore the influencing factors in the multidisciplinary treatment (MDT) modality. Methods: A retrospective analysis was performed. The cases with invasive TNBC who underwent surgery and MDT discussion for adjuvant treatment in Ruijin Hospital, from April 2013 to June 2015, were recruited. The patients' clinicopathological characteristics were analyzed and adjuvant treatment suggestions from MDT were obtained. Here the chemotherapy decision alteration was defined as a disagreement in chemotherapy or not, or inconsistence in regimens between the attending doctor and the multidisciplinary team. Results: A total of 194 patients aged ≤70 years old were enrolled in the multidisciplinary discussion, and 187 patients (96.4%) were suggested to receive chemotherapy. When compared the opinions of the attending doctor to suggestions of the multidisciplinary team, we found that the percentage of chemotherapy decision alteration reached 22.7% (39/172), of which 94.9% (37/39) were inconsistence in chemotherapy regimens. There were 119 patients who were recommended to receive epirubicin plus cyclophosphamide (EC) followed by docetaxel (T) or weekly paclitaxel (wP) regimens. Before the announcement of results for the E1199 trial, EC-T accounted for 62.5% (55/88), and EC-wP accounted for 37.5% (33/88) for this group of patients. After that, the proportion of EC-T was decreased to 22.6% (7/31) and proportion of EC-wP increased to 77.4%(24/31) (P<0.001). In addition, a total of 20 patients were suggested to receive platinum based chemotherapy. The proportions were 9.3% in cases with invasive ductal carcinoma, and 33.3% in cases with metaplastic carcinoma, respectively (P=0.016). Conclusions: The adjuvant chemotherapy decision for TNBC patients is altered in 22.7% of the patients after MDT discussion. After the announcement of SABCS E1199 results, more patients are suggested to receive EC followed by weekly paclitaxel. There is a lack of detailed evidence for platinum based adjuvant chemotherapy for TNBC, and more patients with metaplastic carcinoma receive platinum based adjuvant chemotherapy. 目的: 探讨多学科综合治疗(MDT)模式下三阴性乳腺癌辅助化疗的选择及影响因素。 方法: 回顾性分析2013年4月至2015年6月在上海交通大学医学院附属瑞金医院乳腺疾病诊治中心,接受手术和MDT讨论,并制订术后辅助治疗方案的浸润性三阴性乳腺癌患者的临床病理特征和MDT辅助治疗方案。化疗决策改变定义为主诊医师和MDT团队在化疗与否或化疗方案的意见不一致。 结果: 194例≤70岁的患者中,187例(96.4%)患者推荐予以化疗。主诊医师的意见与MDT团队的推荐意见不一致导致化疗决策的改变率达22.7%(39/172),其中94.9%(37/39)是化疗方案改变。119例患者推荐予以EC-T方案(表柔比星联合环磷酰胺序贯多西他赛)或wP方案(每周紫杉醇)化疗;在E1199研究结果公布前, EC-T方案占62.5%(55/88),EC序贯wP方案占37.5%(33/88); 2014年圣安东尼奥乳腺癌大会(SABCS)E1199研究结果公布后,EC-T方案的比例下降至22.6%(7/31),而EC-wP方案则升高至77.4%(24/31)(P<0.001)。共有20例患者推荐含铂类方案化疗,乳腺浸润性导管癌患者中,推荐铂类化疗方案的患者占9.3%(15/162);化生性癌患者中,推荐含铂类化疗方案的患者占33.3%(5/15),差异有统计学意义(P=0.016)。 结论: MDT模式下三阴性乳腺癌辅助化疗决策的改变率为22.7%。SABCS E1199结果公布后,推荐EC序贯wP辅助化疗方案增多。铂类药物在三阴性乳腺癌辅助化疗中缺乏详实数据,较多化生性癌患者接受含铂类药物辅助化疗。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Hong J, Chen XS, Wu JY, et al. [Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28104032. doi:10.3760/cma.j.issn.0253-3766.2017.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。